Midazolam maleate
Buccolam, Midazolam, Midozalam, Nayzilam, Seizalam (midazolam maleate) is a small molecule pharmaceutical. Midazolam maleate was first approved as Versed on 1985-12-20. It is used to treat anxiety disorders, psychomotor agitation, and status epilepticus in the USA. It has been approved in Europe to treat epilepsy.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| midazolam | ANDA | 2025-04-16 |
| midazolam hcl | unapproved drug other | 2016-04-06 |
| midazolam hydrochloride | ANDA | 2025-03-24 |
| midazolam in sodium chloride | ANDA | 2025-03-02 |
| mkh dose pack | unapproved drug other | 2019-03-05 |
| mko melt dose pack | unapproved drug other | 2019-03-04 |
| n/a | New Drug Application | 2024-05-09 |
| nayzilam | New Drug Application | 2023-01-19 |
| seizalam | New Drug Application | 2023-01-26 |
| versed guards up daily mineral sunscreen broad spectrum spf 35 | OTC monograph final | 2022-08-30 |
Show 1 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MIDAZOLAM, NAYZILAM, UCB INC | |||
| 2026-05-17 | ODE-243 | ||
MIDAZOLAM HYDROCHLORIDE, SEIZALAM, MMT | |||
| 2025-09-14 | ODE-207 | ||
HCPCS
No data
Clinical
Clinical Trials
1566 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 188 | 1 | 1 | 2 | 6 | 198 |
| Anesthesia | D000758 | — | — | 4 | 2 | 7 | 19 | 24 | 54 |
| Postoperative pain | D010149 | — | G89.18 | 3 | 6 | 4 | 15 | 27 | 51 |
| Neoplasms | D009369 | — | C80 | 34 | 3 | 2 | 2 | 8 | 47 |
| Depression | D003863 | — | F33.9 | 9 | 15 | 9 | 7 | 8 | 42 |
| Delirium | D003693 | — | R41.0 | 5 | 1 | 3 | 15 | 17 | 41 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 1 | 6 | 2 | 13 | 18 | 39 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 8 | 13 | 7 | 8 | 7 | 38 |
| Pain | D010146 | EFO_0003843 | R52 | 7 | 3 | — | 10 | 13 | 33 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 2 | 4 | 2 | 10 | 15 | 32 |
Show 273 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Status epilepticus | D013226 | EFO_0008526 | G41 | 1 | 2 | 9 | — | 4 | 15 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 9 | 3 | — | 1 | 11 |
| Traumatic stress disorders | D040921 | — | — | — | 6 | 2 | — | 1 | 8 |
| Hypoxia | D000860 | — | R09.02 | — | — | 2 | — | 6 | 8 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | — | 6 | 7 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | 2 | — | 5 | 7 |
| Adenoma | D000236 | — | — | — | — | 1 | — | 5 | 6 |
| Renal insufficiency | D051437 | — | N19 | 3 | — | 3 | — | — | 6 |
| Suicide | D013405 | — | — | — | 3 | 1 | — | 1 | 5 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 4 | — | 1 | — | — | 5 |
Show 68 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 6 | 2 | — | — | — | 7 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 5 | 1 | — | — | — | 6 |
| Dermatitis | D003872 | — | L30.9 | 5 | 1 | — | — | — | 6 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 4 | 2 | — | — | — | 5 |
| Eczema | D004485 | — | L30.9 | 4 | 1 | — | — | — | 5 |
| Carcinoma | D002277 | — | C80.0 | 2 | 1 | — | — | 2 | 4 |
| Operative surgical procedures | D013514 | — | — | — | 2 | — | — | 2 | 4 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | 3 | — | — | 1 | 4 |
| Leukemia | D007938 | — | C95 | 3 | 2 | — | — | — | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 2 | — | — | — | 3 |
Show 57 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 29 | — | — | — | 3 | 32 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 11 | — | — | — | — | 11 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 6 | — | — | — | 1 | 7 |
| Overweight | D050177 | — | E66.3 | 6 | — | — | — | — | 6 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 6 | — | — | — | — | 6 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | 4 | 5 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 4 | — | — | — | 1 | 5 |
| Melanoma | D008545 | — | — | 4 | — | — | — | — | 4 |
| Food-drug interactions | D018565 | — | — | 3 | — | — | — | 1 | 4 |
| Hepatitis c | D006526 | — | B19.2 | 4 | — | — | — | — | 4 |
Show 106 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiopulmonary bypass | D002315 | — | — | — | — | — | — | 4 | 4 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 3 | 3 |
| Tachycardia | D013610 | — | R00.0 | — | — | — | — | 3 | 3 |
| Airway management | D058109 | — | — | — | — | — | — | 3 | 3 |
| Epidural analgesia | D015360 | — | — | — | — | — | — | 2 | 2 |
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 2 | 2 |
| Thoracic surgical procedures | D019616 | — | — | — | — | — | — | 2 | 2 |
| Anterograde amnesia | D020324 | — | R41.1 | — | — | — | — | 2 | 2 |
| Intraoperative awareness | D058926 | — | — | — | — | — | — | 2 | 2 |
| Gastrointestinal microbiome | D000069196 | — | — | — | — | — | — | 2 | 2 |
Show 172 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Midazolam maleate |
| INN | midazolam |
| Description | Midazolam is an imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively. It has a role as a GABAA receptor agonist, an anticonvulsant, an anxiolytic drug, an apoptosis inducer, an antineoplastic agent, a muscle relaxant, a sedative, a general anaesthetic and a central nervous system depressant. It is an organochlorine compound, an imidazobenzodiazepine and a member of monofluorobenzenes. |
| Classification | Small molecule |
| Drug class | Benzodiazepine |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2.O=C(O)/C=C\C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 59467-70-8 |
| RxCUI | 6960 |
| ChEMBL ID | CHEMBL2106922 |
| ChEBI ID | — |
| PubChem CID | 4192 |
| DrugBank | DB00683 |
| UNII ID | R60L0SM5BC (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 56,454 documents
View more details
Safety
Black-box Warning
Black-box warning for: Midazolam, Midazolam hydrochloride, Midazolam in sodium chloride, N/a, Nayzilam, Seizalam
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,929 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use